A Clinical Study to Evaluate the Efficacy and Safety of Hemocoagulase Injection

• 18-75 years;
• Hemoptysis >=100 mL within 24 hours;
• Bronchiectasis diagnosed by chest high resolution CT;
• Patient, family or guardian is willing to sign the informed consent form.

Exclusion Criteria:

• With severe hepatic or renal insufficiency, ALT>3 ULN, creatinine clearance \<30 mL/min or serum creatinine ≥200 µmol/L or ≥2.5 mg/dL;
• Uncontrollable hypertension (SBP>180mmHg or DBP>110mmHg) or hypotension shock (SBP\<90 mmHg) at randomization;
• History of thrombosis, patients who have undergone thrombosis, or who have severe hematologic diseases;
• Patient with bleeding caused by DIC or vascular disease;

• Patient with coagulation dysfunction

  1. INR>2
  2. Patient with abnormal coagulation function or other bleeding disease (including clinical congenital bleeding disorders, such as von Willebrand disease or acquired hemophilia; hemorrhagic disease; and significant unexplained hemorrhagic disease)
  3. Platelet count \<100×109 /L;
• known allergic to aspirin, clopidogrel, heparin, snake venom blood clotting enzyme, or any component in the study drug allergy or allergic constitution;
• Women who are pregnant or lactating and women of child-bearing agewho do not take reliable contraceptive measures;
• Patients who are or are planning to participate in other clinical trials during the study period;
• Within 72 hours before using the following products including Hemocoagulase For Injection (邦亭®), injection spearhead haemocoagulase (巴曲亭®), Haemocoagulase Agkistrodon for Injection (苏灵®), Hemocoagulase Atrox for Injection (立止血®), leaf pigment or other hemostatic agents;
• Life expectancy of less than 3 months;
• Any other patients who have been judged unfit to participate in this clinical study, including those who are unable or unwilling to comply with the protocol requirements;
• Patients who had participated in other clinical studies within three months prior to the study.